BVF entities disclose shares, 6.05M pre‑funded warrants in Foghorn (FHTX)
A group of Biotechnology Value Fund (BVF) entities and Mark N. Lampert have disclosed their beneficial ownership in Foghorn Therapeutics Inc. (FHTX) via an amended Schedule 13G filing. As of March 31, 2026, the group holds 3,164,410 shares through BVF, 2,218,382 shares through BVF2, and 6,050,782 pre-funded warrants, although exercise is limited by blockers. The filing details various Series Warrants and clarifies ownership percentages based on 58,700,246 shares outstanding as of February 27, 2026, indicating a collective beneficial ownership of up to 9.99% for some entities due to regulatory limits.
How this was made
The 30-second read
Why it matters
Significant insider holdings and warrants suggest strategic positioning, which may impact stock liquidity and investor confidence.
Market read
Ownership disclosures are relevant for investors monitoring institutional activity and potential share dilution effects.
What to watch
Potential for future dilution due to warrants exercise; broader market conditions and company fundamentals remain critical.
Background
Foghorn Therapeutics is a biotech company with ongoing research and development activities; ownership disclosures can influence investor perception.
Ticker impact
High relevance due to significant insider ownership disclosures and potential impact on share price and investor sentiment.
Potential short-term increase in stock volatility; long-term impact uncertain without further fundamental developments.
Ownership disclosures are factual and can influence investor sentiment; however, the actual market reaction depends on broader market conditions and investor interpretations.
High relevance as the news directly pertains to the company's ownership structure and potential market implications.
Possible moderate upward movement in stock price over the next 1-2 weeks; downside risk if market interprets holdings as a sign of future dilution or strategic shifts.
Ownership changes are significant but do not guarantee immediate price movements; market sentiment and broader factors will influence actual outcomes.
Market effects
Increased institutional interest in biotech therapeutics, possibly boosting sector sentiment.
Primarily affects US-based biotech stocks; limited global impact.
Low; specific to US biotech sector and company-level ownership disclosures.
Counterpoint
Institutional ownership disclosures may lead to short-term trading noise without fundamental change; long-term investors should await further developments.
Key entities
- Institutional InvestorBVF entities
A group of investment funds involved in biotech investments.
- Individual InvestorMark N. Lampert
An investor with notable holdings in FHTX.
- CompanyFoghorn Therapeutics Inc.
Biotech firm focused on gene regulation therapies.